FI943579L - Bentsokondensoituja 5-rengasheterosyklejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä, niiden käyttö diagnostisina aineina sekä niitä sisältävät lääkkeet - Google Patents

Bentsokondensoituja 5-rengasheterosyklejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä, niiden käyttö diagnostisina aineina sekä niitä sisältävät lääkkeet Download PDF

Info

Publication number
FI943579L
FI943579L FI943579A FI943579A FI943579L FI 943579 L FI943579 L FI 943579L FI 943579 A FI943579 A FI 943579A FI 943579 A FI943579 A FI 943579A FI 943579 L FI943579 L FI 943579L
Authority
FI
Finland
Prior art keywords
medicines
benzofused
preparation
diagnostic agents
ring heterocycles
Prior art date
Application number
FI943579A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI943579A7 (fi
FI943579A0 (fi
Inventor
Hans-Jochen Lang
Andreas Weichert
Jan-Robert Schwark
Wolfgang Scholz
Udo Albus
Peter Crause
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4326005A external-priority patent/DE4326005A1/de
Priority claimed from DE19944414316 external-priority patent/DE4414316A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of FI943579A0 publication Critical patent/FI943579A0/fi
Publication of FI943579A7 publication Critical patent/FI943579A7/fi
Publication of FI943579L publication Critical patent/FI943579L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FI943579A 1993-08-03 1994-08-01 Bentsokondensoituja 5-rengasheterosyklejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä, niiden käyttö diagnostisina aineina sekä niitä sisältävät lääkkeet FI943579L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4326005A DE4326005A1 (de) 1993-08-03 1993-08-03 Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
DE19944414316 DE4414316A1 (de) 1994-04-25 1994-04-25 Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament

Publications (3)

Publication Number Publication Date
FI943579A0 FI943579A0 (fi) 1994-08-01
FI943579A7 FI943579A7 (fi) 1995-02-04
FI943579L true FI943579L (fi) 1995-02-04

Family

ID=25928286

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943579A FI943579L (fi) 1993-08-03 1994-08-01 Bentsokondensoituja 5-rengasheterosyklejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä, niiden käyttö diagnostisina aineina sekä niitä sisältävät lääkkeet

Country Status (11)

Country Link
EP (1) EP0639573A1 (enExample)
JP (1) JPH07145149A (enExample)
KR (2) KR100343292B1 (enExample)
CN (1) CN1118347A (enExample)
AU (1) AU682371B2 (enExample)
CA (1) CA2129301A1 (enExample)
FI (1) FI943579L (enExample)
HU (1) HU218790B (enExample)
IL (1) IL110503A (enExample)
NO (1) NO301584B1 (enExample)
NZ (1) NZ264130A (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2121391A1 (en) * 1993-04-28 1994-10-29 Atsuyuki Kojima Indoloylguanidine derivatives
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
ES2173182T3 (es) * 1994-04-11 2002-10-16 Chugai Pharmaceutical Co Ltd Derivado de 4,6-dl-butil-2,3-dihidrobenzotiofenos como antioxidantes de ldl.
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2160600A1 (en) * 1994-10-18 1996-04-19 Masahumi Kitano Indoloylguanidine derivatives
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
DE69603771T2 (de) * 1995-04-18 2000-09-07 Hoechst Ag Substituierte Indenoylguanidines mit antiarrhythmischer und cardioprotektiver Wirkung
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19548708A1 (de) * 1995-12-23 1997-06-26 Merck Patent Gmbh Cyclische Sulfone
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
CA2195697A1 (en) 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
WO1997031611A2 (en) * 1996-03-01 1997-09-04 Chiron Corporation Treatment of begnin prostatic hyperplasia
WO1998055475A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Guanidine deriviatives as inhibitors of na+/h+ exchange in cells
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
US6011059A (en) * 1997-12-24 2000-01-04 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
PT1042287E (pt) * 1997-12-24 2005-08-31 Aventis Pharma Gmbh Derivados de indole como inibidores do factor xa
CA2260499A1 (en) * 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
KR20030078886A (ko) * 1998-02-27 2003-10-08 화이자 프로덕츠 인크. 허혈 치료용 ｎ-[(치환된 5원 트리아자 이불포화고리)카르보닐] 구아니딘 유도체
AU769778B2 (en) * 1998-11-05 2004-02-05 Toyama Chemical Co. Ltd. Novel compounds and pharmaceutical use thereof
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
JP2002542291A (ja) 1999-04-23 2002-12-10 ブリストル−マイヤーズ スクイブ カンパニー ジ環式アシルグアニジン・ナトリウム／プロトン交換抑制剤および方法
WO2001044186A1 (en) 1999-12-16 2001-06-21 Sumitomo Pharmaceuticals Company, Limited Substituted guanidine derivatives
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
PL401638A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
FR2842525B1 (fr) * 2002-07-16 2005-05-13 Aventis Pharma Sa Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842526B1 (fr) * 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
WO2004092346A2 (en) 2003-04-15 2004-10-28 The Regents Of The University Of California Small molecule inhibition of a pdz-domain interaction
FR2856062B1 (fr) * 2003-06-12 2005-11-11 Aventis Pharma Sa Derives 3-guanidinocarbonyl-heterocycle, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
ZA200610357B (en) 2004-06-18 2008-02-27 Biolipox Ab Indoles useful in the treatment of inflammation
MX2007000150A (es) 2004-07-01 2007-03-30 Univ California Inhibicion de moleculas pequenas de la interaccion del domini pdz.
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
EP1831192B1 (en) * 2004-12-27 2011-08-24 Korea Research Institute Of Chemical Technology Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same
MX2007008759A (es) 2005-01-19 2007-09-11 Biolipox Ab Indoles utiles en el tratamiento de la inflamacion.
KR100644385B1 (ko) * 2005-02-25 2006-11-10 동양수기산업(주) 흡입식 슬러지 수집기
WO2007018168A1 (ja) 2005-08-08 2007-02-15 Astellas Pharma Inc. アシルグアニジン誘導体またはその塩
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
WO2007065820A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
KR20080114688A (ko) 2006-01-13 2008-12-31 와이어쓰 5-히드록시트립타민 수용체에 대한 리간드로서의 술포닐 치환된 1ｈ-인돌
JP5157893B2 (ja) 2006-02-20 2013-03-06 アステラス製薬株式会社 ピロール誘導体またはその塩
CN101384550B (zh) * 2006-02-20 2011-08-31 安斯泰来制药株式会社 酰胺衍生物或其盐
ES2805286T3 (es) * 2006-12-26 2021-02-11 Lantheus Medical Imaging Inc Ligandos para la formación de imágenes de la inervación cardíaca
CA2787785C (en) 2010-01-28 2018-03-06 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
SG182629A1 (en) 2010-02-18 2012-08-30 High Point Pharmaceuticals Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014047427A2 (en) 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
US10005728B2 (en) 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
AU2015235944B2 (en) 2014-03-27 2020-06-25 Vanderbilt University Substituted indole Mcl-1 inhibitors
CN112961149A (zh) 2014-08-11 2021-06-15 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
CN105884675A (zh) * 2014-09-24 2016-08-24 中国药科大学 N-取代吲哚羧酸衍生物、其制法及医药用途
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN107531631B (zh) 2014-12-31 2021-09-03 安吉昂生物医药公司 用于治疗疾病的方法和药剂
CN109153643B (zh) 2016-03-04 2022-06-21 范德比尔特大学 取代的吲哚mcl-1抑制剂
CN105820132B (zh) * 2016-05-12 2018-11-13 广西师范大学 N-芳基苯并三唑类氮氧衍生物及其合成方法
CN105968059B (zh) * 2016-05-12 2018-11-13 广西师范大学 N-烯基苯并三唑类氮氧衍生物及其制备方法和应用
CN108997172B (zh) * 2018-08-08 2020-12-15 中国人民解放军总医院 抗肿瘤化合物
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN113967210B (zh) * 2020-07-24 2025-02-07 上海交通大学医学院附属瑞金医院 一种干扰整合素β3/Src相互作用的化合物的用途
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202334139A (zh) 2021-11-09 2023-09-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物
KR102767180B1 (ko) 2024-10-17 2025-02-14 효림이엔아이 주식회사 슬러지 수집 안정성이 향상된 원형 슬러지 수집기

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544670A (en) * 1982-08-24 1985-10-01 William H. Rorer, Inc. Method of treating coccidiosis with acyl guanidines
DE3304019A1 (de) * 1983-02-07 1984-08-09 Kali-Chemie Pharma Gmbh, 3000 Hannover 3-acyloxy-1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
DE4127026A1 (de) * 1991-08-16 1993-02-18 Boehringer Ingelheim Kg Neue pyrazinderivate, ihre herstellung und verwendung

Also Published As

Publication number Publication date
NZ264130A (en) 1995-12-21
CA2129301A1 (en) 1995-02-04
KR100343292B1 (ko) 2002-12-26
NO942864L (no) 1995-02-06
JPH07145149A (ja) 1995-06-06
AU682371B2 (en) 1997-10-02
HU218790B (hu) 2000-12-28
AU6884494A (en) 1995-02-16
CN1118347A (zh) 1996-03-13
EP0639573A1 (de) 1995-02-22
NO942864D0 (enExample) 1994-08-02
KR950005512A (ko) 1995-03-20
FI943579A7 (fi) 1995-02-04
HUT70547A (en) 1995-10-30
HU9402271D0 (en) 1994-09-28
IL110503A0 (en) 1994-10-21
IL110503A (en) 2000-06-29
KR950005817A (ko) 1995-03-20
FI943579A0 (fi) 1994-08-01
NO301584B1 (no) 1997-11-17

Similar Documents

Publication Publication Date Title
FI943579L (fi) Bentsokondensoituja 5-rengasheterosyklejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä, niiden käyttö diagnostisina aineina sekä niitä sisältävät lääkkeet
DE69020629D1 (de) Schichtartiges piezoelektrisches Element und Verfahren zu dessen Herstellung.
FI942599A7 (fi) Substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI954105A7 (fi) Uusia 4-aminopyridiinejä, niiden valmistusmenetelmä sekä näitä yhdisteitä sisältäviä lääkkeitä
TR199600144A2 (tr) Benzopiran ihtiva eden bilesikler ve bunlarin kullanimina ait usul.
FI940378A0 (fi) 5-jäseniset heterosyklit, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät lääkeaineet
FI962246A7 (fi) Apoptoosia inhiboivat koostumukset, koostumusten puhdistusmenetelmät j a niiden käyttö
FI930601A7 (fi) 3,5-substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
NO954694D0 (no) Doseringsform for antidepressiva
NO20022254D0 (no) Injeksjonsspröyte
DE69622949D1 (de) Eine Arretiervorrichtung für eine Spritze
DE69333470D1 (de) Olefincopolymere und verfahren zu ihrer herstellung
FI951681A7 (fi) Substituoidut N-heteroaroyyliguanidiinit, menetelmä niiden valmistamiseksi niiden käyttö lääkeaineina tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI943548A7 (fi) Substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
BR9301922A (pt) Transdutor para medicao de forca
FI942598A7 (fi) Substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
BR9105406A (pt) Benzodiazepinonas,compostos,cetonas,processo para a preparacao de compostos,medicamento e uso
FI935825L (fi) 2,4-substituoidut 5-(N-substituoitu-sulfamoyyli)-bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
DE58905246D1 (de) Heterocyclische substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
FI941776A7 (fi) Menetelmä 1,2,4-tiadiatsolien valmistamiseksi
FI953256L (fi) Hyperglykemian vastaisesti vaikuttava lääkeaine
FI953173A7 (fi) Orto-aminosubstituoituja bentsolyyliguanidiinejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
BR9301923A (pt) Transdutor para medicao de forca
FI943853L (fi) Diasyylisubstituoidut guanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
TR27462A (tr) Sübstitüe edilmis sinamik asidi hidroksiamid'leri, bunlarin üretilmesine mahsus usul, bunlari ihtiva eden maddeler ve bunlarin kullanilmasi.